Clinical Trials Logo

Filter by:
NCT ID: NCT03842774 Completed - Obesity Clinical Trials

Efficacy and Safety of Extract of Gelidium Elegans

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

Extract of Gelidium elegans inhibits lipid differentiation, accumulation, and synthesis in vitro and in vivo. It has also anti-obesity effect by inhibiting weight gain and decreasing body fat. In a preliminary study of obese adults aged 20 years or older, the extracts of Gelidium elegans showed a tendency to decrease in body fat and visceral fat, and to increase lean body mass. Based on these results, we tried to confirm the effect of body weight and body fat reduction of Gelidium elegans extract in overweight and obese people.

NCT ID: NCT03841994 Active, not recruiting - Preterm Infants Clinical Trials

Association of Gut Microbiome With Neonatal Complications and Neurodevelopment in Preterm Infants

Start date: December 4, 2018
Phase:
Study type: Observational

A prospective cohort study investigating the effect of the formation of gut microbiome on the neonatal disease and the prognosis of neurodevelopment in preterm infants.

NCT ID: NCT03841968 Not yet recruiting - Ultrasonography Clinical Trials

Dynamic SAX vs Conventional LAX in Internal Jugular Vein Catheterization

Start date: March 2, 2019
Phase: N/A
Study type: Interventional

Conventionally, short-axis out-of-plane (SAX) or long-axis in-plane (LAX) ultrasound views are commonly used to guide internal jugular vein catheterization. SAX dynamic needle tip positioning (SAX-DNTP) is a novel ultrasound imaging technique that enables continuous visualization of the needle tip during ultrasound-guided cannulation; When the needle tip is imaged as a hyperechoic dot, the ultrasound probe is moved a few millimeters, and then the needle is advanced until the needle tip reappears in the vessel lumen. The process is repeated until the needle is advanced more than 1 cm into the lumen. The catheter is then introduced into the vessel. The aim of this study was to compare the first pass success rate of internal jugular vein catheterization between SAX-DNTP and the conventional LAX technique.

NCT ID: NCT03840291 Not yet recruiting - Atrial Fibrillation Clinical Trials

Resolution of Thrombi in Left Atrial Appendage With Edoxaban

REFLEX
Start date: August 2019
Phase: Phase 4
Study type: Interventional

Non-valvular (NV) atrial fibrillation (AF) increases the risk of stroke by approximately fivefold. The atrial thrombi associated with AF are seen within the left atrial appendage (LAA) in most cases (> 90%). Anticoagulation with a vitamin-K antagonist (VKA) is recommended to prevent thromboembolic complications and to resolve thrombi. Non-VKA oral anticoagulants (NOACs) have replaced the VKA for the thromboprophylaxis in patients with NVAF since 2010. Therefore, NOAC can be the excellent alternative to VKA concerning resolving preexisting LAA thrombi because of its rapid onset of action and no need of bridging with heparin. However, there is still lack of data regarding the optimal treatment for patients with AF and thrombi in LAA with NOAC. There are only several case reports of the efficacy of NOACs in resolving LAA thrombi available. Edoxaban, which has data showing efficacy and safety in thromboprophylaxis, can be the new option for treatment of patients with AF and LAA thrombi. The purpose of this study is to evaluate the efficacy of Edoxaban in resolving the LAA thrombi, which is related with nonvalvular AF.

NCT ID: NCT03840200 Not yet recruiting - Breast Cancer Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Start date: March 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study in participants with advanced breast, ovarian, or prostate cancer to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of ipatasertib in combination with rucaparib. The study consists of two parts: a Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer and a Dose-Expansion Phase (Part 2) in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).

NCT ID: NCT03840070 Recruiting - Penile Enhancement Clinical Trials

The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile Enhancement

Start date: December 24, 2018
Phase: N/A
Study type: Interventional

This clinical study is for small-penis syndrome males who have previously been treated with hyaluronic acid filler for the purpose of increasing their penis. This study will determine the long-term efficacy and safety of Potenfill.

NCT ID: NCT03839251 Recruiting - Schizophrenia Clinical Trials

Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

The aim of the study is to investigate the effectiveness of Aripiprazole long-acting injection in recent onset and chronic schizophrenia patients

NCT ID: NCT03838718 Recruiting - Clinical trials for Retroperitoneal Sarcoma

REtroperitoneal SArcoma Registry: an International Prospective Initiative

RESAR
Start date: September 1, 2016
Phase:
Study type: Observational [Patient Registry]

Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: - to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. - patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: - to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; - to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; - to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; - to utilize collected pathological material for research collaborations.

NCT ID: NCT03838406 Recruiting - Clinical trials for BRCA Gene Rearrangement

BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss. And the investigators evaluated the possibility of BRCA loss as a predictive and prognostic factor.

NCT ID: NCT03838380 Completed - Clinical trials for Gestational Diabetes Mellitus in Pregnancy

Smartphone Application for the Management of Gestational Diabetes Mellitus

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The prevalence of gestational diabetes mellitus (GDM) has been progressively increasing. It is important to recognize and treat GDM to minimize the risk of maternal and neonatal complications. Multifaceted professional interventions are effective in the management of GDM and mobile healthcare can be an effective approach. The purpose of the current study was to develop and evaluate a model for prevention and management of GDM using mobile healthcare. Subjects with no previous history of diabetes, who were diagnosed with GDM during 24-28 weeks of gestation, were randomly divided into a conventional management group and a mobile management group. The conventional mangement group received conventional GDM management and could freely use the mobile healthcare application. The mobile management group received mobile healthcare services including tailored mobile coaching. The effectiveness of the management using the application were evaluated through the result values of the laboratory tests, anthropometric measurement performed during the study period and perinatal outcomes.